Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments

Abstract : Crohn's disease (CD) requires treatment beyond symptoms by enabling and maintaining mucosal healing and therefore clinical remission. However, with the increasing use of biologics there have been safety concerns and there is a significant cost implication with the early use of biologics. Therefore, it is imperative that patients with severe/complicated disease or poor prognostic factors are treated with an aggressive strategy while all remaining patients should be treated in a step-up strategy. The potential for disease modification with thiopurines and methotrexate is debated in CD when they are used as a monotherapy. In this review we discuss existing and newer therapies that have recently been developed for CD. We will also provide an algorithm for current management of adult CD patients in routine clinical practice.
Type de document :
Article dans une revue
Expert Review of Clinical Immunology, Expert Reviews (formerly Future Drugs), 2016, 12 (7), pp.741 - 749. 〈10.1586/1744666X.2016.1154789〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01662854
Contributeur : Ngere Ul <>
Soumis le : mercredi 13 décembre 2017 - 14:55:14
Dernière modification le : lundi 23 avril 2018 - 15:53:23

Identifiants

Collections

Citation

Patrick Allen, Laurent Peyrin-Biroulet. Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments. Expert Review of Clinical Immunology, Expert Reviews (formerly Future Drugs), 2016, 12 (7), pp.741 - 749. 〈10.1586/1744666X.2016.1154789〉. 〈hal-01662854〉

Partager

Métriques

Consultations de la notice

18